Bevacizumab biosimilar(Enzene Biosciences)

N/A

Report date: 2024/09/04 09:30:31

Base Information

Drug NameBevacizumab biosimilar(Enzene Biosciences)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEnzene Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEnzene Biosciences Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A